Concepedia

Andrew Spaltenstein

AS

Statistics

Publications

32

Citations

1.5K

H-Index

22

Active since

1993

Affiliations

Research Triangle Park Foundation(Current)

GlaxoSmithKline (United States)

Vertex Pharmaceuticals (United States)

GlaxoSmithKline (United Kingdom)

Burroughs Wellcome Fund

Andrew Spaltenstein is an author at Research Triangle Park Foundation specializing in medicinal chemistry, drug discovery, and antiviral pharmacology.

Publications per year

1993–2013

32

Publications

32

Polyacrylamides Bearing Pendant .alpha.-Sialoside Groups Strongly Inhibit Agglutination of Erythrocytes by Influenza A Virus: Multivalency and Steric Stabilization of Particulate Biological Systems

Watson J. Lees, Andrew Spaltenstein, Jill Kingery-Wood et al. · Journal of Medicinal Chemistry · 1994 · 191 citations

, , +5

Preclinical Pharmacology and Pharmacokinetics of GW433908, a Water-Soluble Prodrug of the Human Immunodeficiency Virus Protease Inhibitor Amprenavir

Eric S. Furfine, Christopher Baker, Michael Hale et al. · Antimicrobial Agents and Chemotherapy · 2004 · 98 citations · Full text

, , +15

Imidazopyridine-5,6,7,8-tetrahydro-8-quinolinamine derivatives with potent activity against HIV-1

Kristjan S. Gudmundsson, Sharon Boggs, John G. Catalano et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 85 citations

, , +10

Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents

John F. Miller, Elizabeth M. Turner, Kristjan S. Gudmundsson et al. · Bioorganic & Medicinal Chemistry Letters · 2010 · 84 citations · Full text

, , +14

Ultra-potent P1 modified arylsulfonamide HIV protease inhibitors: The discovery of GW0385

John F. Miller, C. Webster Andrews, Michael Brieger et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 78 citations · Full text

, , +14

1–5 of 32